These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 32911945

  • 1. Assessment of the efficacy of photodynamic therapy in patients with chronic central serous chorioretinopathy.
    Manethová K, Ernest J, Hrevuš M, Jirásková N.
    Cesk Slov Oftalmol; 2020; 75(6):298-308. PubMed ID: 32911945
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
    Hua L, Lin B, Hong J, Min HB, Han WL, Zhou TY, Zhang ZQ.
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
    [Abstract] [Full Text] [Related]

  • 7. Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.
    Russo A, Turano R, Morescalchi F, Gambicorti E, Cancarini A, Duse S, Costagliola C, Semeraro F.
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1141-1148. PubMed ID: 28283732
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, Song SJ, Park TK, Moon SW, Chung H.
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy].
    Li L, Yuan F, Xu GZ, Wang WJ.
    Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):106-13. PubMed ID: 22490944
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
    Hayashida M, Miki A, Honda S, Nakamura M.
    Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
    [Abstract] [Full Text] [Related]

  • 16. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M.
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [Abstract] [Full Text] [Related]

  • 17. Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin.
    Chan WM, Lam DS, Lai TY, Yuen KS, Liu DT, Chan CK, Chen WQ.
    Am J Ophthalmol; 2003 Nov; 136(5):836-45. PubMed ID: 14597034
    [Abstract] [Full Text] [Related]

  • 18. Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Kumashiro S, Takagi S, Itokawa T, Tajima A, Kobayashi T, Hori Y.
    BMC Ophthalmol; 2021 May 31; 21(1):241. PubMed ID: 34053440
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.